Biocryst Pharmaceuticals (BCRX) Acquisitions (2026)
Biocryst Pharmaceuticals' (BCRX) quarterly Acquisitions came in at $489.5 million in Q1 2026.
Powered by 
Analysis
Biocryst Pharmaceuticals (BCRX) Acquisitions (2026) Analysis & Trends
Biocryst Pharmaceuticals (BCRX) has reported Acquisitions for 1 consecutive years, with $489.5 million the latest figure, recorded in Q1 2026.
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Acquisitions (Qtr) |
|---|---|---|---|---|---|
| 1 | Amgen | 211.56 Bn | 197.57 Bn | 7.24 Bn | - |
| 2 | Gilead Sciences | 181.34 Bn | 178.16 Bn | 6.22 Bn | 11.21 Bn |
| 3 | Vertex Pharmaceuticals | 132.22 Bn | 124.37 Bn | 2.84 Bn | - |
| 4 | Regeneron Pharmaceuticals | 82.87 Bn | 74.88 Bn | 3.93 Bn | - |
| 5 | Argenx Se | 61.55 Bn | 56.37 Bn | 1.37 Bn | - |
| 6 | Moderna | 54.32 Bn | 49.19 Bn | 52.00 Mn | - |
| 7 | Alnylam Pharmaceuticals | 34.32 Bn | 31.01 Bn | 992.69 Mn | - |
| 8 | Biogen | 31.24 Bn | 29.95 Bn | 1.96 Bn | - |
| 9 | Roivant Sciences | 30.17 Bn | 30.17 Bn | 1.16 Mn | - |
| 10 | Biocryst Pharmaceuticals | 2.31 Bn | 1.95 Bn | 214.41 Mn | - |